Greenland Mines Hosts Briefing on Mining and Biotech Projects
格陵蘭礦業公司舉辦採礦與生物技術項目簡報會
In a bold strategic shift, Klotho Neurosciences has officially rebranded as Greenland Mines Ltd (Nasdaq: GRML).
在一場大膽的戰略轉型中，Klotho Neurosciences正式更名為Greenland Mines Ltd（納斯達克代碼：GRML）。
Based in Charlotte, North Carolina, the company has adopted a unique dual-business model that combines high-tech gene therapy with Arctic natural resource exploration.
該公司總部位於北卡羅來納州夏洛特市，採用了獨特的雙重商業模式，將高科技基因療法與北極自然資源探勘相結合。
While continuing to advance its KLTO-202 therapy candidate for Amyotrophic Lateral Sclerosis (ALS), the company is aggressively pursuing the Skaergaard Project in southeast Greenland.
在繼續推進其針對肌萎縮性脊髓側索硬化症（ALS）的KLTO-202候選療法之同時，該公司正積極開展位於格陵蘭島東南部的Skaergaard計畫。
To ensure environmental compliance, the company is conducting multi-year biological surveys and has joined the Greenland Business Association to foster local economic ties.
為確保符合環保規範，公司正在進行多年期的生物調查，並已加入格陵蘭商業協會以促進當地經濟聯繫。
Despite this massive potential, the company faces significant hurdles, including Nasdaq compliance challenges regarding its minimum bid price.
儘管潛力巨大，該公司仍面臨重大阻礙，包括納斯達克關於最低投標價格的合規性挑戰。
By diversifying into mining, Greenland Mines aims to stabilize its risk profile and attract a broader range of investors, creating an unlikely synergy between medical innovation and heavy industry as it works toward a sustainable future in the Arctic.
透過跨足礦業，Greenland Mines旨在穩定其風險概況並吸引更廣泛的投資者，在致力於實現北極永續未來的同時，為醫療創新與重工業創造了一種不可思議的協同效應。
